Poor
Noncompliant
Patient Risk:
High
Summary
Only the insomnia indication claim is supported by the provided label sections. Several mechanism/clinical-effect and specific side-effect prevalence claims are unsupported or not verifiable from the available labeling excerpts, and safety-critical labeling elements are omitted.
Category Scores
Accurate Statements
Quviviq (daridorexant) is a medication prescribed for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Supported by 1 INDICATIONS AND USAGE.
Quviviq is a dual orexin receptor antagonist.
Partially supported/wording mismatch: 11 DESCRIPTION states daridorexant is an orexin receptor antagonist, but the provided excerpts do not verify the specific modifier 'dual'.
Common side effects associated with Quviviq may include sleep paralysis.
Partially supported: sleep paralysis is listed under 6 ADVERSE REACTIONS (frequency not provided).
Common side effects associated with Quviviq may include hallucinations.
Partially supported: hypnagogic/hypnopompic hallucinations are listed under 6 ADVERSE REACTIONS (frequency not provided).
Unsupported Statements
Quviviq is a dual orexin receptor antagonist.
Not verifiable from the provided label excerpts regarding 'dual' receptor antagonism; only 'orexin receptor antagonist' wording is shown in the available section.
Quviviq works by blocking the wake-promoting signals in the brain.
Mechanism wording is not present in the provided label excerpts.
Clinical trials have demonstrated that Quviviq can reduce the time it takes to fall asleep.
The required support is in 14 CLINICAL STUDIES, which is not provided in the available label sections.
Clinical trials have demonstrated that Quviviq can improve the ability to stay asleep.
The required support is in 14 CLINICAL STUDIES, which is not provided in the available label sections.
Common side effects associated with Quviviq may include vivid dreams.
No 'vivid dreams' wording is present in the provided label excerpts.
Common side effects associated with Quviviq may include troublesome dreams.
No 'troublesome dreams' wording is present in the provided label excerpts.
Quviviq has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA).
Regulatory approval status is not supported by the provided label excerpts.
Contradictions
Important Omissions
Contraindications (e.g., narcolepsy; history of hypersensitivity to daridorexant or components).
Importance:
High
Warnings and precautions content (section 5), including labeling topics referenced in 6 ADVERSE REACTIONS.
Importance:
High
Dosage and administration (including dosing regimen/safety limitations), and any administration instructions.
Importance:
High
Boxed warning status (if any) and other key safety labeling elements relevant to prescribing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The extracted response includes multiple unsupported/uncorroborated mechanistic and clinical-effect claims and mischaracterizes adverse events as 'common' without frequency support. It also omits contraindications and warnings/precautions, which are safety-critical labeling elements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Noncompliant
Primary Issue
Multiple claims are unsupported or not verifiable from the provided label excerpts, and safety-critical labeling elements (contraindications/warnings/dosing) are omitted.
Suggested Improvement
Restrict claims to provided label-supported text (e.g., indication). Remove or qualify unsupported mechanism/clinical-trial and 'common' prevalence statements unless frequency data are present in the provided labeling. Include contraindications and warnings/precautions references/content consistent with the label when making safety-related statements.